Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Allecra Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Allecra and Acino sign deal for Exblifep antibiotic in GCC, South Africa
Details : Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance.
Brand Name : Exblifep
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 25, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Allecra Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : Aspen Pharmacare Holdings
Deal Size : $119.4 million
Deal Type : Acquisition
Acino Acquires Selected Aspen Brands in South Africa
Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.
Brand Name : Trustan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 22, 2021
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : Aspen Pharmacare Holdings
Deal Size : $119.4 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
